In vitro platelet function in controlled ovarian hyperstimulation cycles

Abstract

Objective: To determine the effects of elevated endogenous E 2 levels on in vitro platelet function in patients undergoing controlled ovarian hyperstimulation (COH). Design: Women with normal ovulatory cycles and patients undergoing COH on cycle day 3 and near ovulation (preovulatory follicles were at least 16 mm in diameter) were studied. Serum E 2, Thrombostat 4000, (V. d. Goltz, Seeon, Germany), von Willebrand factor antigen (vWF-Ag), and platelet aggregation and adenosine triphosphate (ATP) release to adenosine diphosphate (ADP), collagen (COL), and arachidonic acid (AA) were measured. Setting: University-based outpatient infertility clinic. Patient(s): Twenty-two consenting infertile women undergoing COH cycles and 14 women with documented ovulatory cycles. Main Outcome Measure(s): Whole blood platelet aggregation with ADP, COL, AA, and Thrombostat 4000. Result(s): Estradiol levels rose significantly at peak times (P = 0.011). No changes were noted in in vitro platelet function measured by the Thrombostat 4000 and by whole blood platelet aggregation with ADP and AA and in ATP release with ADP, COL, or AA. Aggregation with collagen was increased because of likely elevations in vWF-Ag levels. Conclusion(s): No significant changes in in vitro platelet function were noted in 19 women undergoing COH with E 2 levels two to three times that observed in oral contraceptive or hormone replacement therapy users, suggesting no increased risk for arterial thromboembolism.